Cargando…

The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer

Alterations in the glycosylation of serum total immunoglobulins show these antibodies to have a diagnostic potential for cancer but the disease-related Abs to the tumor-associated antigens, including glycans, have still poorly been investigated in this respect. We analysed serum samples from patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtenkov, Oleg, Innos, Kaire, Sergejev, Boris, Klaamas, Kersti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076901/
https://www.ncbi.nlm.nih.gov/pubmed/30105268
http://dx.doi.org/10.1155/2018/9579828
_version_ 1783344801842724864
author Kurtenkov, Oleg
Innos, Kaire
Sergejev, Boris
Klaamas, Kersti
author_facet Kurtenkov, Oleg
Innos, Kaire
Sergejev, Boris
Klaamas, Kersti
author_sort Kurtenkov, Oleg
collection PubMed
description Alterations in the glycosylation of serum total immunoglobulins show these antibodies to have a diagnostic potential for cancer but the disease-related Abs to the tumor-associated antigens, including glycans, have still poorly been investigated in this respect. We analysed serum samples from patients with breast carcinoma (n = 196) and controls (n = 64) for the level of Thomsen-Friedenreich (TF) antigen-specific antibody isotypes, their sialylation, interrelationships, and the avidity by using ELISA with the synthetic TF-polyacrylamide conjugate as an antigen and the sialic acid-specific Sambucus nigra agglutinin (SNA) and ammonium thiocyanate as a chaotrope. An increased sialylation of IgG and IgM, but a lower SNA reactivity of IgA TF antibodies, and a higher level and avidity of the TF-specific IgA were found in cancer patients. Other cancer-related signatures were the highly significant increase of the IgG/IgA ratio and the very low SNA/IgA index in cancer, including patients with an early stage of the disease. These changes showed a good diagnostic potential with about 80% accuracy. Thus, the level of naturally occurring anti-TF antigen antibodies, their sialylation profile, isotype distribution, and avidity displayed cancer-specific changes that could serve as novel noninvasive Ab-based biomarkers for early breast cancer.
format Online
Article
Text
id pubmed-6076901
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60769012018-08-13 The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer Kurtenkov, Oleg Innos, Kaire Sergejev, Boris Klaamas, Kersti Biomed Res Int Research Article Alterations in the glycosylation of serum total immunoglobulins show these antibodies to have a diagnostic potential for cancer but the disease-related Abs to the tumor-associated antigens, including glycans, have still poorly been investigated in this respect. We analysed serum samples from patients with breast carcinoma (n = 196) and controls (n = 64) for the level of Thomsen-Friedenreich (TF) antigen-specific antibody isotypes, their sialylation, interrelationships, and the avidity by using ELISA with the synthetic TF-polyacrylamide conjugate as an antigen and the sialic acid-specific Sambucus nigra agglutinin (SNA) and ammonium thiocyanate as a chaotrope. An increased sialylation of IgG and IgM, but a lower SNA reactivity of IgA TF antibodies, and a higher level and avidity of the TF-specific IgA were found in cancer patients. Other cancer-related signatures were the highly significant increase of the IgG/IgA ratio and the very low SNA/IgA index in cancer, including patients with an early stage of the disease. These changes showed a good diagnostic potential with about 80% accuracy. Thus, the level of naturally occurring anti-TF antigen antibodies, their sialylation profile, isotype distribution, and avidity displayed cancer-specific changes that could serve as novel noninvasive Ab-based biomarkers for early breast cancer. Hindawi 2018-07-15 /pmc/articles/PMC6076901/ /pubmed/30105268 http://dx.doi.org/10.1155/2018/9579828 Text en Copyright © 2018 Oleg Kurtenkov et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kurtenkov, Oleg
Innos, Kaire
Sergejev, Boris
Klaamas, Kersti
The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title_full The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title_fullStr The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title_full_unstemmed The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title_short The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer
title_sort thomsen-friedenreich antigen-specific antibody signatures in patients with breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076901/
https://www.ncbi.nlm.nih.gov/pubmed/30105268
http://dx.doi.org/10.1155/2018/9579828
work_keys_str_mv AT kurtenkovoleg thethomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT innoskaire thethomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT sergejevboris thethomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT klaamaskersti thethomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT kurtenkovoleg thomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT innoskaire thomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT sergejevboris thomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer
AT klaamaskersti thomsenfriedenreichantigenspecificantibodysignaturesinpatientswithbreastcancer